HECTOR GUILLEN: Open Payments
NPI 1891386942 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,252 in 175 payments from 13 companies in 2025. Trend: 2023 $1,434 · 2024 $2,456 · 2025 $3,252
Food & beverage: $3,252
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 34 | $561 |
| Otsuka America Pharmaceutical, Inc. | 27 | $448 |
| ABBVIE INC. | 26 | $440 |
| Corium, LLC | 20 | $425 |
| Axsome Therapeutics, Inc. | 13 | $283 |
| E.R. Squibb & Sons, L.L.C. | 12 | $271 |
| Teva Pharmaceuticals USA, Inc. | 15 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $188 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $107 |
| Neurocrine BioSciences, Inc. | 5 | $100 |
Products named: REXULTI, VRAYLAR, Azstarys, ARISTADA, Auvelity, COBENFY, TRINTELLIX, LYBALVI.
Industry payments across TX — which companies pay providers there.
